156 related articles for article (PubMed ID: 32845191)
21. Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR TKI Therapy.
Wu B; Gu X; Zhang Q
J Thorac Oncol; 2018 Feb; 13(2):184-193. PubMed ID: 29101057
[TBL] [Abstract][Full Text] [Related]
22. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
[TBL] [Abstract][Full Text] [Related]
23. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
24. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
25. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.
Ahn MJ; Han JY; Kim DW; Cho BC; Kang JH; Kim SW; Yang JC; Mitsudomi T; Lee JS
Cancer Res Treat; 2020 Jan; 52(1):284-291. PubMed ID: 31345012
[TBL] [Abstract][Full Text] [Related]
26. Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial.
Nakao A; Hiranuma O; Uchino J; Sakaguchi C; Kita T; Hiraoka N; Ishizuka T; Kubota Y; Kawasaki M; Goto Y; Imai H; Hattori N; Nakatomi K; Uramoto H; Uryu K; Fukuda M; Uchida Y; Yokoyama T; Akai M; Mio T; Nagashima S; Chihara Y; Tamiya N; Kaneko Y; Mouri T; Yamada T; Yoshimura K; Fujita M; Takayama K
Oncologist; 2019 May; 24(5):593-e170. PubMed ID: 30651400
[TBL] [Abstract][Full Text] [Related]
27. Divergent
Rehman M; Kim C; Reuss JE; Kiedrowski LA; Garg RJ; Liu SV
JCO Precis Oncol; 2021 Nov; 5():939-942. PubMed ID: 34994624
[No Abstract] [Full Text] [Related]
28. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
[TBL] [Abstract][Full Text] [Related]
29. Uncommon
Okuma Y; Shimokawa M; Hashimoto K; Mizutani H; Wakui H; Murakami S; Atagi S; Minato K; Seike M; Ohe Y; Kubota K;
Future Oncol; 2022 Feb; 18(5):523-531. PubMed ID: 35034503
[TBL] [Abstract][Full Text] [Related]
30. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment.
Sueoka-Aragane N; Nakashima C; Yoshida H; Matsumoto N; Iwanaga K; Ebi N; Nishiyama A; Yatera K; Kuyama S; Fukuda M; Ushijima S; Umeguchi H; Harada D; Kashiwabara K; Suetsugu T; Fujimoto N; Tanaka F; Uramoto H; Yoshii C; Nakatomi K; Koh G; Seki N; Aoe K; Nosaki K; Inoue K; Takamori A; Kawaguchi A
Cancer Med; 2021 Jun; 10(12):3873-3885. PubMed ID: 33982444
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
Wakuda K; Yamaguchi H; Kenmotsu H; Fukuda M; Takeshita M; Suetsugu T; Kirita K; Ebi N; Hataji O; Miura S; Chibana K; Okamoto I; Yoshimura K; Nakagawa K; Yamamoto N; Sugio K
BMC Cancer; 2020 May; 20(1):370. PubMed ID: 32357848
[TBL] [Abstract][Full Text] [Related]
32. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.
Minari R; Bordi P; La Monica S; Squadrilli A; Leonetti A; Bottarelli L; Azzoni C; Lagrasta CAM; Gnetti L; Campanini N; Petronini PG; Alfieri R; Tiseo M
J Thorac Oncol; 2018 Jun; 13(6):e89-e91. PubMed ID: 29596911
[No Abstract] [Full Text] [Related]
33. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
Okuno T; Arakawa S; Yoshida T; Ohe Y
Lung Cancer; 2020 May; 143():95-96. PubMed ID: 32209253
[No Abstract] [Full Text] [Related]
35. Overall Survival with Osimertinib in Untreated,
Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC;
N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of osimertinib in patients with lung adenocarcinoma in clinical practice - the Expanded Drug Access Program in Poland.
Knetki-Wróblewska M; Kowalski DM; Czyżewicz G; Bryl M; Wrona A; Dziadziuszko R; Kieszko R; Milanowski J; Świniuch D; Ramlau R; Krzakowski M
Adv Respir Med; 2020; 88(3):189-196. PubMed ID: 32706102
[TBL] [Abstract][Full Text] [Related]
38. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
39. Emerging EML4-ALK Variant 5 as a Concurrent Resistance Mechanism to Osimertinib in a Patient With EGFR E19del/T790M NSCLC.
Yan Y; Jiang G; Ma W; Li T; Wang L
Clin Lung Cancer; 2020 Nov; 21(6):562-567. PubMed ID: 32622727
[No Abstract] [Full Text] [Related]
40. Efficacy of osimertinib for the treatment of previously EGFR TKI treated NSCLC patients: a meta-analysis.
Li ZX; Zhao W; Sun Q; Tang MS; Xia QJ; Dong MS
Clin Transl Oncol; 2020 Jun; 22(6):892-899. PubMed ID: 31538306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]